July 27, 2020 — QuartzBio’s Tobias Guennel, PhD, presented the following poster, “A Genetic Enrichment Strategy for Delay of Onset of Alzheimer’s Disease Clinical Trials,” at AAIC 2020.
A Genetic Enrichment Strategy for Delay of Onset of Alzheimer’s Disease Clinical Trials
Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments. Precision for Medicine is part of Precision Medicine Group, with 3,000 employees in 40 locations.
QUARTZBIO® and the PRECISION QUARTZBIO logo® are registered trademarks of Precision Medicine Group, LLC in the United States and/or other jurisdictions. All rights reserved. The names and logos of other companies and products appearing on the website may be trademarks or registered trademarks of such other companies.